Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study

NCT02500446 is registered in ClinicalTrials.gov with University of Melbourne as lead sponsor.

NCT NCT02500446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02500446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study
Lead sponsor
University of Melbourne
Phase
Phase 4
Overall status
Completed
Start date
September 28, 2015
Completion date
September 30, 2017
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv